210 related articles for article (PubMed ID: 12742844)
1. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results.
Gillies MC; Simpson JM; Luo W; Penfold P; Hunyor AB; Chua W; Mitchell P; Billson F
Arch Ophthalmol; 2003 May; 121(5):667-73. PubMed ID: 12742844
[TBL] [Abstract][Full Text] [Related]
2. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial.
Gillies MC; Simpson JM; Billson FA; Luo W; Penfold P; Chua W; Mitchell P; Zhu M; Hunyor AB
Arch Ophthalmol; 2004 Mar; 122(3):336-40. PubMed ID: 15006845
[TBL] [Abstract][Full Text] [Related]
3. Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: one-year results.
Lee J; Freeman WR; Azen SP; Chung EJ; Koh HJ
Retina; 2007; 27(9):1205-13. PubMed ID: 18046226
[TBL] [Abstract][Full Text] [Related]
4. Intereye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide.
Jonas JB; Spandau UH; Harder B; Vossmerbaeumer U; Kamppeter BA
Am J Ophthalmol; 2005 Jun; 139(6):1073-9. PubMed ID: 15953439
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration.
Jonas JB; Akkoyun I; Budde WM; Kreissig I; Degenring RF
Arch Ophthalmol; 2004 Feb; 122(2):218-22. PubMed ID: 14769599
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.
Jonas JB
Acta Ophthalmol Scand; 2005 Dec; 83(6):645-63. PubMed ID: 16396641
[TBL] [Abstract][Full Text] [Related]
7. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial.
Chaudhary V; Mao A; Hooper PL; Sheidow TG
Ophthalmology; 2007 Dec; 114(12):2183-9. PubMed ID: 18054638
[TBL] [Abstract][Full Text] [Related]
8. Photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: a randomized clinical trial.
Maberley D;
Ophthalmology; 2009 Nov; 116(11):2149-57.e1. PubMed ID: 19748675
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration.
Danis RP; Ciulla TA; Pratt LM; Anliker W
Retina; 2000; 20(3):244-50. PubMed ID: 10872928
[TBL] [Abstract][Full Text] [Related]
10. Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration.
Jonas JB; Spandau UH; Kamppeter BA; Harder B
Eye (Lond); 2007 Mar; 21(3):387-94. PubMed ID: 16410809
[TBL] [Abstract][Full Text] [Related]
11. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema.
Cardillo JA; Melo LA; Costa RA; Skaf M; Belfort R; Souza-Filho AA; Farah ME; Kuppermann BD
Ophthalmology; 2005 Sep; 112(9):1557-63. PubMed ID: 16019075
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial.
Gillies MC; Sutter FK; Simpson JM; Larsson J; Ali H; Zhu M
Ophthalmology; 2006 Sep; 113(9):1533-8. PubMed ID: 16828501
[TBL] [Abstract][Full Text] [Related]
13. Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography.
Hatta Y; Ishikawa K; Nishihara H; Ozawa S; Ito Y; Terasaki H
Retina; 2010 Mar; 30(3):495-502. PubMed ID: 19996828
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial.
Sutter FK; Simpson JM; Gillies MC
Ophthalmology; 2004 Nov; 111(11):2044-9. PubMed ID: 15522370
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
16. Effect of posterior juxtascleral triamcinolone acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin.
Van de Moere A; Sandhu SS; Kak R; Mitchell KW; Talks SJ
Ophthalmology; 2005 Nov; 112(11):1896-903. PubMed ID: 16214216
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract.
Gillies MC; Kuzniarz M; Craig J; Ball M; Luo W; Simpson JM
Ophthalmology; 2005 Jan; 112(1):139-43. PubMed ID: 15629834
[TBL] [Abstract][Full Text] [Related]
18. Micropulsed laser photocoagulation and intravitreal triamcinolone acetonide injection for the treatment of retinal angiomatous proliferation.
Roth DB; Scott IU; Gloth JM; Green SN; Yarian DL; Wheatley M
Retina; 2007; 27(9):1201-4. PubMed ID: 18046225
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal triamcinolone acetonide: a change in a paradigm.
Jonas JB
Ophthalmic Res; 2006; 38(4):218-45. PubMed ID: 16763379
[TBL] [Abstract][Full Text] [Related]
20. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up.
Challa JK; Gillies MC; Penfold PL; Gyory JF; Hunyor AB; Billson FA
Aust N Z J Ophthalmol; 1998 Nov; 26(4):277-81. PubMed ID: 9843254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
